Newman Dignan & Sheerar Inc’s Clearside Biomedical CLSD Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,008	Closed	-$24.1K	–	183
2025 Q2	$24.1K	Hold	2,008	–	–	0.01%	190
2025 Q1	$27.6K	Hold	2,008	–	–	0.01%	169
2024 Q4	$28.6K	Buy	2,008 +140	+7%	+$2.3K	0.01%	176
2024 Q3	$30.8K	Buy	+1,868	New	+$31.9K	0.01%	182
2024 Q1	–	Sell	-1,868	Closed	-$32.8K	–	174
2023 Q4	$32.8K	Buy	+1,868	New	+$26.6K	0.01%	172
2023 Q3	–	Sell	-1,802	Closed	-$30.3K	–	169
2023 Q2	$30.3K	Hold	1,802	–	–	0.01%	183
2023 Q1	$28.1K	Hold	1,802	–	–	0.01%	189
2022 Q4	$30.3K	Hold	1,802	–	–	0.01%	186
2022 Q3	$31	Buy	+1,802	New	+$39.5K	﹤0.01%	177
2022 Q2	–	Sell	-1,802	Closed	-$62	–	184
2022 Q1	$62	Buy	1,802 +80	+5%	+$2.39K	0.01%	190
2021 Q4	$71K	Buy	1,722 +287	+20%	+$18.6K	0.02%	196
2021 Q3	$129K	Buy	+1,435	New	+$127K	0.04%	183
2021 Q2	–	Sell	-1,535	Closed	-$57K	–	185
2021 Q1	$57K	Buy	+1,535	New	+$77.1K	0.02%	177

Other funds holding CLSD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Newman Dignan & Sheerar Inc's CLSD Position: Q3 2025 in Review

Newman Dignan & Sheerar Inc sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 2,008 shares — an estimated $24.1K sold.

Newman Dignan & Sheerar Inc first reported a position in CLSD in Q1 2021 and held it in 13 quarters. The position peaked at $129K in Q3 2021. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.

Newman Dignan & Sheerar Inc reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
Newman Dignan & Sheerar Inc sold 2,008 Clearside Biomedical shares in Q3 2025, an estimated $24.1K.
Newman Dignan & Sheerar Inc first reported a position in Clearside Biomedical in Q1 2021 and held it in 13 quarters.
Newman Dignan & Sheerar Inc's Clearside Biomedical position peaked at $129K in Q3 2021.
26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q3 2025, filed 9 Oct 2025.